Elahere, which is a pioneering FRα-targeting ADC, has exhibited a favourable benefit-risk safety profile in the treatment of platinum-resistant epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Here, FOLR1 is linked to ovarian carcinoma.